Cunmian Pharmaceutical

Cunmian Pharmaceutical is a China-based biotechnology company focused on the discovery and development of innovative immunotherapies for the treatment of cancer and other immune-related diseases. The company leverages its proprietary drug discovery platform to identify novel targets and develop high-affinity monoclonal antibodies and small molecule inhibitors. Their research primarily targets immune checkpoints and the tumor microenvironment to enhance the body's natural anti-tumor response. Headquartered in Shanghai, Cunmian aims to address unmet medical needs through precision medicine and advanced biologics. The company is currently advancing several programs through the pre-clinical stage with a focus on next-generation oncology treatments.